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published in the English language from dates of inception to
January 2007. Patients were considered to have CHB if they had
elevated ALT levels and active viral replication. Monotherapy,
combination and sequential therapies were included. Among
trials that met our inclusion criteria, we abstracted data describ-
ing normalization of ALT, HBV DNA, sustained biochemical
response, HBeAg seroconversion, histological improvement,
drop-outs and adverse events. Intention-to-treat data were com-
bined using a random-effects meta-analysis, with missing data
considered as treatment failures. Outcomes were expressed as
relative risks with 95% conﬁdence intervals. RESULTS: The
initial search yielded 2064 references, 127 were excluded due to
inadequate blinding, allocation concealment, randomization and
reporting of outcomes; 20 studies were included. Trials involved
5573 patients (4121 males, 1309 females), ranging in size from
200–814 patients. Mean age was 40.7. Eleven trials studied
HBeAg-positive patients, four trials studied HBeAg-negative
patients, and four trials studied both. Due to small numbers of
trials for comparison led to pooling of HBeAg-positive and
HBeAg-negative studies. No treatment was superior for all
outcome measures. Monotherapy was superior to placebo. Com-
parisons of single drugs favored treatment with ADF or ENT
over LAM or PEG. LAM was superior to PEG with better clinical
outcomes and fewer adverse events and patient dropouts. Com-
bination and sequential treatments were not superior, however
comparisons were limited by our one-year follow-up. CONCLU-
SION: Monotherapy with ADF or ENT are the most attractive
treatment options within the ﬁrst year of treatment. Further
research on combination and sequential therapies may provide
better options but presently insufﬁcient evidence exists to support
this approach.
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OBJECTIVE: The purpose of this study is to investigate treat-
ment options of osteomyelitis based on physician decisions
recorded in our dataset. METHODS: We want to ﬁnd the fre-
quency of a given input (code) for a variable, or more than one
variable in health care data. Using the Thomson MedStat
MarketScan data containing all patient claims for 40 million
observations, the primary diagnosis code is given for each
patient as well as ﬁfteen possible secondary diagnoses. We use
SAS Text Miner to demonstrate a simpliﬁed method to search
these ﬁfteen columns. We use ICD9 and CPT codes to ﬁnd
treatments for osteomyelitis. We also look for sequential treat-
ments for recurrence of osteomyelitis. After ﬁltering the data for
Osteomyelitis, there are 18,721 observations in inpatients that
contain 2661 patients, and 233,001 observations in outpatients
with 78,957 patients. RESULTS: The difference between the
number of observation and number of distinct patient IDs
shows that most patients have a sequence of procedures during
their treatment. After sorting the data by procedures, the most
frequent (20%) is “Dorsal and dorsolumbar fusion, posterior
technique”, second is “Excisional debridement of wound, infec-
tion, or burn” (15%), third “Amputation of toe” (9%), and in
forth place, “Revision of amputation stump” (7%). In the out-
patient data, the most frequent procedure is code 86.59
(Closure of skin and subcutaneous tissue of other sites) with
4021 records out of 8711 records. We found that about 8 % of
patients with osteomyelitis from inpatient data and about 0.3%
from outpatient data had amputation. CONCLUSION: While
amputation does not occur as often as debridement, we want to
examine the sequence of treatments to see whether amputation
follows a pattern of debridement.
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OBJECTIVE: To determine antimicrobial resistance proﬁles for
Enterococcus in 14 tertiary-level hospitals in Bogotá, Colombia.
METHODS: Time series analyses were performed, as well as
descriptive analyses of Enterococcus faecalis and Enterococcus
faecium in hospitals belonging to the Bogotá Bacterial Resistance
Control Group from January 1, 2001–January 1, 2007. We
identiﬁed the presence and species of enterococcus according to
anatomical site. RESULTS: During that period, a total of 5770
strains of Enterococci faecalis and 1259 of Enterococcus faecium
were analyzed. Enterococcus was found in >20% of isolates from
blood samples and abdominal ﬂuid in critical care units (SUCI)
and in >10% of samples from non-critical care services (SNUCI)
in tertiary-level hospitals in Bogotá. Ampicillin was active against
Enterococcus faecalis strains in Critical care units (SUCI) and
other services (SNUCI), but >50% of E.faecium strains in SNUCI
were resistant. Vancomycin-resistant strains occurred in >2%
of E.faecalis strains identiﬁed in SUCI and >8% in SNUCI.
The resistance trend in E.faecium to vancomycin in SNUCI was
towards the low in the six years studied. CONCLUSION: This
study conﬁrms the worldwide trend towards an increase in infec-
tions due to Enterococcus. The emerging pattern of antimicrobial
resistance among such isolates is alarming.
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OBJECTIVE: The danger of widespread and intense epidemics of
yellow fever (YF) in Africa has become very serious, requiring
urgent immunization response. Because it is not possible to vac-
cinate 100% of the adult population, the challenge is to prioritize
immunization of the population at highest risk. An original risk
assessment has been performed at the initiative of the World
Health Organization, using modeling to enable countries to
deﬁne populations currently at highest risk, which will be vacci-
nated in priority. METHODS: Five exposure risk factors have
been selected and collected at the district level in three African
countries: Burkina Faso, Togo, Mali. The ﬁve indicators are:
ecological risk zone, conﬁrmed YF cases since 1960, suspected
cases since 1960, number of years in which YF cases notiﬁed
since 1960, district close to another district that has notiﬁed cases
since 1960. A multi-criteria analysis based on multiple compo-
nent analysis (MCA) has constructed a composite exposure indi-
cator (CEi) from the ﬁve selected exposure risk factors. In
reducing by mathematical projections the number of dimensions,
MCA modeling synthesize complex data tables. RESULTS: For
each of the three target countries, three analyses have been done
for rural districts, urban districts and rural + urban districts.
Four risk clusters have been determined from the lowest risk to
the highest risks, allowing the construction of detailed YF risk
maps in Burkina-Faso, Togo and Mali. These “YF risk assess-
ment maps” present in four colors the four risk clusters at each
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district level. CONCLUSION: This approach seem to be an
original, robust and reproducible technique for risk assessment
purpose, which can be applied to a number of diseases and
technology assessment when the number of indicators (risk indi-
cators, clinical indicators, biologic indicators, etc) make data
interpretation, comparisons and decision making difﬁcult.
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OBJECTIVE: Methicillin-resistant Staphylococcus aureus, or
MRSA, is a commonly acquired infection in the hospital envi-
ronment. We examine data from the National Inpatient Sample
(NIS) to diagnose trends to gain more insight about the infection.
It is the purpose of this study to determine if race, age or gender
are factors in the severity of the infection, and to ascertain what
effects any secondary conditions may have on a patient with
MRSA. METHODS: The data were collected from a 10%
sample from 2004 from the NIS with information relevant to
5974 patients diagnosed with MRSA. The data were then
imported into SAS Enterprise Guide 4. SAS is used to create
tables of data and kernel density estimates, which give an esti-
mate of the data’s probability density, to develop a logistic regres-
sion model relating death risk to speciﬁc diagnoses, and to
develop a linear model concerning a patient’s total charges.
RESULTS: There appears to be a correlation between the age of
a patient and the length of inpatient stay. Asian American and
African American patients experience a higher mortality rate
with MRSA. Total charges were similar between males and
females, although males showed a slightly higher mean; second-
ary conditions and age had a much more pronounced effect on
charges. The three most common conditions present in patients
with MRSA were hypertension, urinary tract infection (UTI), and
congestive heart failure—UTI and heart failure appear to raise
the risk of death to one with MRSA. CONCLUSIONS: Further
studies should be conducted to investigate MRSA and how it
affects people from various ethnic backgrounds and age groups.
By analyzing medical data and performing kernel density esti-
mates, it is possible to uncover important relationships that can
be used to treat patients worldwide.
INFECTION—Cost Studies
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OBJECTIVE: Quantify the budgetary impact of adding a new
carbapenem, doripenem, to a hospital formulary for treatment
of complicated intra-abdominal infection (cIAI), complicated
urinary tract infection (cUTI) and nosocomial pneumonia (NP)
including ventilator-associated pneumonia (VAP), in the United
States. Doripenem has been approved in the US for cIAI and
cUTI and is under FDA review for treatment of NP, including
VAP. METHODS: This model was developed in accordance with
Good Research Practices for Budget Impact Analysis dissemi-
nated by ISPOR to estimate the annual impact on a hospital’s
budget of adding doripenem. Carbapenem (doripenem, imi-
penem, meropenem) wholesale acquisition costs from 2007
National Drug Data File, hospitalization costs (2006 US dollars)
from published literature, annual hospital admissions for NP,
VAP, cIAI, and cUTI, current proportional share of imipenem
and meropenem (50% each, no doripenem use), treatment dura-
tion and length of stay (LOS) from clinical trials were considered.
A new proportional share of 50% doripenem, 30% imipenem
and 20% meropenem was assumed for this analysis. Sensitivity
of results on different proportions of doripenem use was exam-
ined. RESULTS: Total cost per treated patient was estimated to
be $24,284 (range: $13,117 (cUTI) to $71,026 (VAP)), prior to
introduction of doripenem. With the new proportional share, it
would decrease to $23,305 (range: $12,987 (cUTI) to $65,289
(VAP)), a 4% reduction in the budget. Pharmacy costs made up
4% of overall treatment costs. The majority of savings came
from shorter hospital LOS for VAP, observed in clinical trials
comparing doripenem to comparators. Scenarios with a greater
proportion of doripenem use resulted in larger savings to the
hospital budget ($1927 per patient at 100% doripenem use).
Results remained favorable for formulary with doripenem under
various sensitivity analyses. CONCLUSION: Results indicate
that adding doripenem to a hospital formulary will yield poten-
tial savings to a hospital’s budget.
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OBJECTIVE: To quantify the workforce and cost implica-
tions of routine doctor-intensive (DI), nurse-intensive (NI) and
pharmacist-intensive (PI) ART follow-up algorithms for HIV/
AIDS treatment at the Infectious Diseases Institute, a large
urban HIV clinic in Kampala, Uganda. METHODS: We per-
formed a societal perspective cost analysis including health
resource utilization and opportunity cost of patient waiting
(PW) time. A time-motion survey was performed to estimate
median health worker utilization (HWU) and PW times for dif-
ferent services. Unique personnel requirements were identiﬁed
to determine hourly HWU per patient, which was multiplied by
hourly wages for different cadres. PW times were multiplied by
mean hourly wage for Ugandans. National workforce and cost
implications were projected. RESULTS: Median HWU and PW
times per visit (hours) were 0.20 and 0.24 for triage nurses,
0.12 and 1.10 for doctors, 0.08 and 0.27 for pharmacists, and
0.13 and 0.05 for nurses. HWU time for reﬁll pharmacists
was 0.03 with no waiting. Hourly wages were: nurses-$4.6,
doctors-$8.3, and pharmacists-$3.3. The average Ugandan
hourly wage was $0.99. Total annual societal per-patient cost
of follow-up was $45.2 for DI, $28.3 for NI and $16.3 for PI.
Total projected national annual follow-up cost was $13.5
million for DI, $8.5 million for NI and $4.9 million for PI.
Extrapolating to a national level, we project that the substitu-
tion of nurses or pharmacists for doctors would save 404 full-
time-equivalent doctors per year, 18.4% of the current
number practicing in Uganda. CONCLUSION: The use of NI
and PI innovations as substitutes for DI follow-up results in
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